Targeting DNA through-covalent interactions of reversible binding drugs.
Graves
D E
DE
Department of Chemistry, University of Mississippi, University, Mississippi 38677, USA.
D000677:Amsacrine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D001483:Base Sequence; D001665:Binding Sites; D004247:DNA / Q000737:chemistry* / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D003609:Dactinomycin / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D015195:Drug Design; D004996:Ethidium / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D066298:In Vitro Techniques; D007364:Intercalating Agents / Q000737:chemistry / Q000378:metabolism; D008024:Ligands; D008958:Models, Molecular; D009690:Nucleic Acid Conformation; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism*; D010777:Photochemistry
D007364:Intercalating Agents; D008024:Ligands; D004364:Pharmaceutical Preparations; D000677:Amsacrine; D003609:Dactinomycin; D004247:DNA; D004250:DNA Topoisomerases, Type II; D004996:Ethidium